Document is current
Any future updates will be listed below
-
Authors
Cevoli, Giulia
Isaia, Ivan
Parvan, Reza
Chen, Horng H.
Malatino, Lorenzo
Burnett, John C. Jr.
Cataliotti, Alessandro https://orcid.org/0000-0001-5476-8523
-
Funding
Funding for this research was provided by:
University of Oslo
- License Information
-
More Information
Article History
Received: 22 May 2026
Accepted: 11 August 2026
First Online: 28 August 2026
Declarations
Conflict of interest: Giulia Cevoli reports grant support from the Norwegian Health Association. Alessandro Cataliotti has received research funding from the Norwegian Health Association, served as a scientific advisor for Madeleine Pharmaceuticals, and is a co-inventor on patents related to natriuretic peptide-based diagnostics and therapies for cardiovascular and renal diseases. John C. Burnett Jr has received NIH funding, is an inventor or co-inventor on multiple patents related to natriuretic peptide-based diagnostics and therapies, and has contributed to the founding of biotechnology companies developing natriuretic peptide-based therapeutics. Horng H. Chen is a co-inventor on patents related to natriuretic peptide-based therapies and is co-founder of Zumbro Discovery Inc. Ivan Isaia, Reza Parvan, and Lorenzo Malatino declare that they have no conflicts of interest relevant to this work.
Ethical statements: As this manuscript is a review article, ethical approval and patient consent were not required.
